Application of nanotechnology to cancer radiotherapy

Mi, Yu; Shao, Zhaogang; Vang, Johnny; Kaidar‐Person, Orit; Wang, Andrew Z.

doi:10.1186/s12645-016-0024-7

Cited by 131 publications

(72 citation statements)

References 86 publications

(96 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[2] Specifically,r adiationbased combination therapy has become aclinical standard in curative and palliative treatment regimens. [3] Recently,radionuclide therapy using particle-emitting radioisotopes (for example, 177 Lu, 90 Y, and 131 I) has presented promising results for the palliative treatment of several cancers. [4] Among those radionuclides,t he increase in 177 Lu applications has enriched its potential for research and therapeutic procedures and established it at the forefront of clinical radionuclide therapy.…”

mentioning

confidence: 99%

Efficient Uptake of ¹⁷⁷Lu‐Porphyrin‐PEG Nanocomplexes by Tumor Mitochondria for Multimodal‐Imaging‐Guided Combination Therapy

et al. 2017

Angew Chem Int Ed

View full text Add to dashboard Cite

The benefits to intracellular drug delivery from nanomedicine have been limited by biological barriers and to some extent by targeting capability.W ei nvestigated as izecontrolled, dual tumor-mitochondria-targeted theranostic nanoplatform (Porphyrin-PEG Nanocomplexes,P PNs). The maximum tumor accumulation (15.6 %ID g À1 ,7 2h p.i.) and ideal tumor-to-muscle ratio (16.6, 72 hp.i.) was achieved using an optimizedP PN particle sizeo fa pproximately 10 nm, as measured by using PET imaging tracing. The stable coordination of PPNs with 177 Lu enables the integration of fluorescence imaging (FL) and photodynamic therapy( PDT) with positron emission tomography (PET) imaging and internal radiotherapy( RT). Furthermore,t he efficient tumor and mitochondrial uptake of 177 Lu-PPNs greatly enhanced the efficacies of RT and/or PDT.T his work developed af acile approach for the fabrication of tumor-targeted multi-modal nanotheranostic agents,w hiche nables precision and radionuclide-based combination tumor therapy.Nanomedicine is renowned for its feasibility and controllability to create all-in-one multi-functional properties for cancer theranostics.[1] Nanoparticle-mediated combinatorial therapeutic regimens are increasingly being used by researchers to improve therapies because of their greater tumor cell killing effects at the targeted site.[2] Specifically,r adiationbased combination therapy has become aclinical standard in curative and palliative treatment regimens.[3] Recently,radionuclide therapy using particle-emitting radioisotopes (for example, 177 Lu, 90 Y, and 131 I) has presented promising results for the palliative treatment of several cancers.[4] Among those radionuclides,t he increase in 177 Lu applications has enriched its potential for research and therapeutic procedures and established it at the forefront of clinical radionuclide therapy.[5] Radioisotope 177 Lu has favorably long nuclear decay properties (t 1/2 = 6.65 d) and can be used to easily radiolabel av ariety of molecular carriers.[6] As such, 177 Lu promises to benefit nanoparticle-mediated combination therapy.Previous studies explored 177 Lu-labeled gold nanoparticles for preclinical nuclear medicine.[7] However,t he clinical translation of the reported nanosystem was impeded because of high and long-term accumulation in the reticuloendothelial system (RES) and low intratumor uptake.T hus,i tr emains ab ig challenge to integrate nanocarrier tumor-targeted delivery and multi-modal imaging using 177 Lu to obtain an anotheranostic agent with high efficiacy.Thespecificity of nanotheranostic reagents to cancer cells is critical for an efficient therapeutic effect with low side effects.[8] Am yriad of strategies have been developed to enhance cancer-targeting specificity,s uch as the conjugation of nanomaterials with target ligands. [9] In ar ecent report, mitochondria targeting emerged as apromising approach for cancer therapy.[10] However,there are several existing fundamental limitations on the design and synthesis of nanomaterials,s uch ...

show abstract

mentioning

confidence: 99%

Efficient Uptake of ¹⁷⁷Lu‐Porphyrin‐PEG Nanocomplexes by Tumor Mitochondria for Multimodal‐Imaging‐Guided Combination Therapy

et al. 2017

Angew Chem Int Ed

View full text Add to dashboard Cite

show abstract

“…Each of the aforementioned techniques individually promote the efficacy of radiation therapy, however, their combination can even achieve greater efficacy. More recently, advancements in nanomaterial fabrications have provided the means to integrate these two techniques in bifunctional material systems . In particular, nanoparticles (NPs) containing elements with high atomic numbers (high‐Z) are excellent X‐ray absorbers, which make them promising agents for CT imaging and as radiosensitizers for external X‐ray radiation therapy (RT) applications …”

Section: Introductionmentioning

confidence: 99%

Engineering Multifunctional Gold Decorated Dendritic Mesoporous Silica/Tantalum Oxide Nanoparticles for Intraperitoneal Tumor‐Specific Delivery

Kashfi‐Sadabad

Gonzalez-Fajardo

Hargrove

et al. 2019

Part & Part Syst Charact

View full text Add to dashboard Cite

Nonspecific high‐energy radiation for treatment of metastatic ovarian cancer is limited by damage to healthy organs, which can be mitigated by the use of radiosensitizers and image‐guided radiotherapy. Gold (Au) and tantalum oxide (TaOx) nanoparticles (NPs), by virtue of their high atomic numbers, find utility in the design of bimetallic NP systems capable of high‐contrast computed tomography (CT) imaging as well as a potential radiosensitizing effect. These two radio‐dense metals are integrated into dendritic mesoporous silica NPs (dMSNs) with radial porous channels for high surface‐area loading of therapeutic agents. This approach results in stable, monodispersed dMSNs with a uniform distribution of Au on the surface and TaOx in the core that exhibits CT attenuation up to seven times greater than iodine or monometallic dMSNs without either TaOx or Au. Tumor targeting is assessed in a metastatic ovarian cancer mouse model. Ex vivo micro‐CT imaging of collected tumors shows that these NPs not only accumulate at tumor sites but also penetrate inside tumor tissues. This study demonstrates that after intraperitoneal administration, rationally designed bimetallic NPs can simultaneously serve as targeted contrast agents for imaging tumors and to enhance radiation therapy in metastatic ovarian cancer.

show abstract

“…Its success is limited due to radiation resistance in melanoma cells (16,34). This technique has been improved by engineering, physics, chemistry, and biology to promote innovative technologies that allow real-time imaging and better dose distribution according to disease progress (67).…”

Section: Nano Therapies: Radiotherapy and Chemotherapymentioning

confidence: 99%

“…Immune response, including opsonization, is another way for radioisotopes clearance by mononuclear phagocytes (MPS). In this context, nanocarriers emerge as an alternative for the half-life increment of radioisotopes (67). Glutathione-coated gold nanostructures represents the next generation of radiosensitizers used for gamma-ray irradiation (34,68).…”

Section: Nano Therapies: Radiotherapy and Chemotherapymentioning

confidence: 99%

“…Seenivasan et al immobilized anti-Melanocortin 1 receptor antibodies (MC1R-Abs) on amino-functionalized silica nanoparticles (n-SiNPs)-polypyrrole (PPy) nanocomposite thin film and used them as an immune sensor for selective and sensitive detection of melanoma cells (66). A magnetite nanoparticle designed by Sato et al by conjugating N-propionyl-cyst aminyl phenol with magnetite was used in a B16F1 xenograft mouse model (67). Souza et al showed that melanoma cells were degraded after the application of an external irregular magnetic field to increase the temperature in the tumor to 43°C.…”

Section: Nanomedicine For Melanoma Detection and Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Nanomedicine in Melanoma: Current Trends and Future Perspectives

El-Kenawy

Constantin

Hassan

et al. 2017

Cutaneous Melanoma: Etiology and Therapy

View full text Add to dashboard Cite

Abstract:As cutaneous melanoma is a highly aggressive and drug-resistant cancer, there is intense research focusing on developing new, efficient drugs. Nanomedicine focuses on developing different groups of nanomaterials for both diagnosis and therapy, and this combination of specific diagnosis and therapy is called theranostics. Nanomaterials tailored as delivery vehicles can be nanocapsules, nanorods, nanotubes, nanoshells, and nanocages. All these structures protect the intended drug against degradation and enhance its stability. The development and characterization of polymeric nanoparticles, polymeric micelles, liposomes, nanohydrogel, dendrimers, inorganic nanoparticles, and hybrid nanocarriers are among the delivery vehicles that transport different anticancer agents. Functionalization of nanocarriers with specific molecules, such as antibodies, can generate different smart nanodrugs for application in cancer therapy and/or diagnosis. Nanotherapeutic strategies deal with several shortcomings that comprise of tumor characteristics, biological barriers, biocompatibility, and so on. As nanostructures interact with various host biomolecules, comprehensive in vitro cellular models call for evaluation of physicochemical properties, dose, and time of action of nanomaterials, while in vivo assessments would provide valuable data regarding the level of absorption, tissue/organ distribution, and metabolism. The future perspectives in nanotechnology applied to cancer overcomes the translational barrier from the laboratory to the clinical application to potentially improve conventional theranostic techniques.

show abstract

Application of nanotechnology to cancer radiotherapy

Cited by 131 publications

References 86 publications

Efficient Uptake of ¹⁷⁷Lu‐Porphyrin‐PEG Nanocomplexes by Tumor Mitochondria for Multimodal‐Imaging‐Guided Combination Therapy

Efficient Uptake of ¹⁷⁷Lu‐Porphyrin‐PEG Nanocomplexes by Tumor Mitochondria for Multimodal‐Imaging‐Guided Combination Therapy

Engineering Multifunctional Gold Decorated Dendritic Mesoporous Silica/Tantalum Oxide Nanoparticles for Intraperitoneal Tumor‐Specific Delivery

Nanomedicine in Melanoma: Current Trends and Future Perspectives

Contact Info

Product

Resources

About

Application of nanotechnology to cancer radiotherapy

Cited by 131 publications

References 86 publications

Efficient Uptake of 177Lu‐Porphyrin‐PEG Nanocomplexes by Tumor Mitochondria for Multimodal‐Imaging‐Guided Combination Therapy

Efficient Uptake of 177Lu‐Porphyrin‐PEG Nanocomplexes by Tumor Mitochondria for Multimodal‐Imaging‐Guided Combination Therapy

Engineering Multifunctional Gold Decorated Dendritic Mesoporous Silica/Tantalum Oxide Nanoparticles for Intraperitoneal Tumor‐Specific Delivery

Nanomedicine in Melanoma: Current Trends and Future Perspectives

Contact Info

Product

Resources

About

Efficient Uptake of ¹⁷⁷Lu‐Porphyrin‐PEG Nanocomplexes by Tumor Mitochondria for Multimodal‐Imaging‐Guided Combination Therapy

Efficient Uptake of ¹⁷⁷Lu‐Porphyrin‐PEG Nanocomplexes by Tumor Mitochondria for Multimodal‐Imaging‐Guided Combination Therapy